


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



C-MER 希瑪

C-MER EYE CARE HOLDINGS LIMITED

希瑪眼科醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3309)

**POSITIVE PROFIT ALERT
FOR THE SIX MONTHS ENDED 30 JUNE 2021**

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of C-MER Eye Care Holdings Limited (the “**Company**”, which together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the inside information provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Based on the information currently available and a preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2021 (“**1H2021**”), the Directors expect that the net profit of the Group for 1H2021 would be within the range of HK\$10.0 million to HK\$15.0 million, as compared with the net loss of the Group for the six months ended 30 June 2020 in the amount of HK\$22.2 million. The turnaround in the Group’s profitability was primarily due to a significant increase in the Group’s revenue by over 90% as compared with the six months ended 30 June 2020 in the amount of HK\$261.8 million, however the effect of revenue increase to the Group’s profits was partially offset by net losses incurred by the Group’s hospitals in their investment stages, including the new hospital in Huizhou (which recently commenced business operations on 31 March 2021) and the eye hospital in Zhuhai (which the Group acquired in August 2020 and commenced business operations on 22 December 2020).

As the Company is still in the process of finalising the results for 1H2021, the information contained in this announcement is based on the management’s preliminary review of the unaudited consolidated management accounts of the Group and information currently available to the Board for 1H2021, and has not been reviewed and confirmed by the Company’s auditors or the audit committee of the Board. Shareholders and potential investors of the Company are advised to read carefully the interim results announcement of the Company for 1H2021, which is expected to be published by the end of August 2021.

Shareholders and prospective investors of the Company are advised to exercise caution when dealings in the shares of the Company.

By order of the Board

C-MER EYE CARE HOLDINGS LIMITED

Dr. LAM Shun Chiu Dennis JP

Chairman and Chief Executive Officer and Executive Director

Hong Kong, 5 August 2021

As of the date of this announcement, the Board comprises four executive Directors, namely Dr. LAM Shun Chiu Dennis, Ms. LI Xiaoting, Dr. LEE Yau Wing Vincent and Mr. LI Chunshan and six independent non-executive Directors, namely, Dr. LI Kwok Tung Donald, Mr. MA Andrew Chiu Cheung, Mr. CHAN Chi Leong, Ms. BENTLEY Annie Liang, Dr. Rex AUYEUNG Pak-kuen and Mr. IP Shu Kwan Stephen.